Published in FASEB J on November 16, 2004
mTOR is a key modulator of ageing and age-related disease. Nature (2013) 5.40
Platelets secrete stromal cell-derived factor 1alpha and recruit bone marrow-derived progenitor cells to arterial thrombi in vivo. J Exp Med (2006) 1.98
Ocular tolerability and efficacy of intravitreal and subconjunctival injections of sirolimus in patients with non-infectious uveitis: primary 6-month results of the SAVE Study. J Ophthalmic Inflamm Infect (2013) 1.85
p21Cip1 modulates arterial wound repair through the stromal cell-derived factor-1/CXCR4 axis in mice. J Clin Invest (2008) 1.14
Inhibition of mTOR attenuates store-operated Ca2+ entry in cells from endarterectomized tissues of patients with chronic thromboembolic pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol (2009) 0.99
Role of mitochondrial reactive oxygen species in age-related inflammatory activation of endothelium. Aging (Albany NY) (2014) 0.98
A review of therapies for diabetic macular oedema and rationale for combination therapy. Eye (Lond) (2015) 0.92
Treatment of geographic atrophy with subconjunctival sirolimus: results of a phase I/II clinical trial. Invest Ophthalmol Vis Sci (2013) 0.85
Adventitial nab-rapamycin injection reduces porcine femoral artery luminal stenosis induced by balloon angioplasty via inhibition of medial proliferation and adventitial inflammation. Circ Cardiovasc Interv (2013) 0.83
One-Year Outcomes of the SAVE Study: Sirolimus as a Therapeutic Approach for UVEitis. Transl Vis Sci Technol (2015) 0.80
Edge restenosis: impact of low dose irradiation on cell proliferation and ICAM-1 expression. BMC Cardiovasc Disord (2006) 0.80
The effects of bare metal versus drug-eluting stent implantation on circulating endothelial cells following percutaneous coronary intervention. J Res Med Sci (2011) 0.80
Multi-scale optical imaging of the delayed type hypersensitivity reaction attenuated by rapamycin. Theranostics (2014) 0.80
Mitochondria-targeted antioxidant SkQ1 improves impaired dermal wound healing in old mice. Aging (Albany NY) (2015) 0.79
Sirolimus inhibits key events of restenosis in vitro/ex vivo: evaluation of the clinical relevance of the data by SI/MPL- and SI/DES-ratios. BMC Cardiovasc Disord (2007) 0.77
A Critical Role of the mTOR/eIF2α Pathway in Hypoxia-Induced Pulmonary Hypertension. PLoS One (2015) 0.75
T-lymphocyte infiltration in visceral adipose tissue: a primary event in adipose tissue inflammation and the development of obesity-mediated insulin resistance. Arterioscler Thromb Vasc Biol (2008) 5.44
Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science (2008) 5.30
Mutations in dynein link motor neuron degeneration to defects in retrograde transport. Science (2003) 4.40
Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum (2005) 4.12
Nuclear signalling by tumour-associated antigen EpCAM. Nat Cell Biol (2009) 4.05
Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. Lancet (2013) 3.83
Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo. J Exp Med (2012) 3.63
Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum (2006) 3.51
A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis (2013) 3.43
Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. Blood (2012) 3.38
The emerging role of EpCAM in cancer and stem cell signaling. Cancer Res (2009) 3.25
Age at disease onset and diagnosis delay in HLA-B27 negative vs. positive patients with ankylosing spondylitis. Rheumatol Int (2002) 2.95
Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. Arthritis Rheum (2008) 2.75
Inflammatory back pain in ankylosing spondylitis: a reassessment of the clinical history for application as classification and diagnostic criteria. Arthritis Rheum (2006) 2.67
Non-invasive measurement of brain viscoelasticity using magnetic resonance elastography. NMR Biomed (2008) 2.66
2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann Rheum Dis (2011) 2.61
High concentrations of therapeutic IgG1 antibodies are needed to compensate for inhibition of antibody-dependent cellular cytotoxicity by excess endogenous immunoglobulin G. Mol Immunol (2005) 2.54
Symptomatic efficacy of etanercept and its effects on objective signs of inflammation in early nonradiographic axial spondyloarthritis: a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol (2014) 2.52
A crucial role of glycoprotein VI for platelet recruitment to the injured arterial wall in vivo. J Exp Med (2003) 2.49
Combined transcriptome and genome analysis of single micrometastatic cells. Nat Biotechnol (2002) 2.48
Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum (2008) 2.48
The early disease stage in axial spondylarthritis: results from the German Spondyloarthritis Inception Cohort. Arthritis Rheum (2009) 2.45
Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores. Ann Rheum Dis (2010) 2.34
Migration of iron oxide-labeled human hematopoietic progenitor cells in a mouse model: in vivo monitoring with 1.5-T MR imaging equipment. Radiology (2005) 2.25
EuroCMR (European Cardiovascular Magnetic Resonance) registry: results of the German pilot phase. J Am Coll Cardiol (2009) 2.23
The impact of aging and gender on brain viscoelasticity. Neuroimage (2009) 2.15
The concept of axial spondyloarthritis: joint statement of the spondyloarthritis research and treatment network and the Assessment of SpondyloArthritis international Society in response to the US Food and Drug Administration's comments and concerns. Arthritis Rheumatol (2014) 2.14
Critical appraisal of assessment of structural damage in ankylosing spondylitis: implications for treatment outcomes. Arthritis Rheum (2008) 2.14
Effect of non-steroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort. Ann Rheum Dis (2012) 2.10
Noninvasive assessment of the rheological behavior of human organs using multifrequency MR elastography: a study of brain and liver viscoelasticity. Phys Med Biol (2007) 2.08
Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two. Arthritis Rheum (2008) 2.04
Platelets secrete stromal cell-derived factor 1alpha and recruit bone marrow-derived progenitor cells to arterial thrombi in vivo. J Exp Med (2006) 1.98
MRI inflammation at the vertebral unit only marginally predicts new syndesmophyte formation: a multilevel analysis in patients with ankylosing spondylitis. Ann Rheum Dis (2011) 1.90
Detection of bone metastases in patients with lung cancer: 99mTc-MDP planar bone scintigraphy, 18F-fluoride PET or 18F-FDG PET/CT. Eur J Nucl Med Mol Imaging (2009) 1.87
Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis. N Engl J Med (2015) 1.83
MR-elastography reveals degradation of tissue integrity in multiple sclerosis. Neuroimage (2009) 1.83
Assessment of liver viscoelasticity using multifrequency MR elastography. Magn Reson Med (2008) 1.80
Down-regulation of the nonspecific and antigen-specific T cell cytokine response in ankylosing spondylitis during treatment with infliximab. Arthritis Rheum (2003) 1.79
Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct. Int J Cancer (2005) 1.77
Aurora kinases A and B are up-regulated by Myc and are essential for maintenance of the malignant state. Blood (2010) 1.76
Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. Ann Rheum Dis (2013) 1.74
Targeting of hematopoietic progenitor cells with MR contrast agents. Radiology (2003) 1.72
Reduction of major adverse cardiac events with intracoronary compared with intravenous bolus application of abciximab in patients with acute myocardial infarction or unstable angina undergoing coronary angioplasty. Circulation (2003) 1.71
Capacity of human monocytes to phagocytose approved iron oxide MR contrast agents in vitro. Eur Radiol (2004) 1.70
CD19-/CD3-bispecific antibody of the BiTE class is far superior to tandem diabody with respect to redirected tumor cell lysis. Mol Immunol (2006) 1.69
MT110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors. Mol Immunol (2005) 1.69
Overexpression of epithelial cell adhesion molecule (Ep-CAM) is an independent prognostic marker for reduced survival of patients with epithelial ovarian cancer. Gynecol Oncol (2006) 1.69
Cabazitaxel plus prednisone for metastatic castration-resistant prostate cancer progressing after docetaxel: results from the German compassionate-use programme. Eur Urol (2012) 1.69
Protein kinase c-β-dependent activation of NF-κB in stromal cells is indispensable for the survival of chronic lymphocytic leukemia B cells in vivo. Cancer Cell (2013) 1.68
In vivo viscoelastic properties of the brain in normal pressure hydrocephalus. NMR Biomed (2010) 1.67
Baseline radiographic damage, elevated acute-phase reactant levels, and cigarette smoking status predict spinal radiographic progression in early axial spondylarthritis. Arthritis Rheum (2012) 1.66
PPAR activators as antiinflammatory mediators in human T lymphocytes: implications for atherosclerosis and transplantation-associated arteriosclerosis. Circ Res (2002) 1.66
Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells. Mol Immunol (2005) 1.64
Myocardial biopsy findings and gadolinium enhanced cardiovascular magnetic resonance in dilated cardiomyopathy. Eur J Heart Fail (2005) 1.57
Concepts and epidemiology of spondyloarthritis. Best Pract Res Clin Rheumatol (2006) 1.57
BiTEs: bispecific antibody constructs with unique anti-tumor activity. Drug Discov Today (2005) 1.54
Blinatumomab: a historical perspective. Pharmacol Ther (2012) 1.52
Fractional encoding of harmonic motions in MR elastography. Magn Reson Med (2007) 1.49
Prevalence of myocardial scar in patients with cryptogenic cerebral ischemic events and patent foramen ovale. JACC Cardiovasc Imaging (2010) 1.48
MR elastography of the human heart: noninvasive assessment of myocardial elasticity changes by shear wave amplitude variations. Magn Reson Med (2009) 1.47
Myocardial biopsy based classification and treatment in patients with dilated cardiomyopathy. Int J Cardiol (2005) 1.45
C/EBPdelta is a crucial regulator of pro-apoptotic gene expression during mammary gland involution. Development (2005) 1.45
In vivo tracking of genetically engineered, anti-HER2/neu directed natural killer cells to HER2/neu positive mammary tumors with magnetic resonance imaging. Eur Radiol (2004) 1.44
Both structural damage and inflammation of the spine contribute to impairment of spinal mobility in patients with ankylosing spondylitis. Ann Rheum Dis (2010) 1.43
Role of bone marrow-derived cells in the genetic control of restenosis. Arterioscler Thromb Vasc Biol (2009) 1.43
Cell tracking with gadophrin-2: a bifunctional contrast agent for MR imaging, optical imaging, and fluorescence microscopy. Eur J Nucl Med Mol Imaging (2004) 1.43
Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab. Exp Cell Res (2011) 1.42
Pioglitazone reduces neointima volume after coronary stent implantation: a randomized, placebo-controlled, double-blind trial in nondiabetic patients. Circulation (2005) 1.42
Asparagine synthetase as a causal, predictive biomarker for L-asparaginase activity in ovarian cancer cells. Mol Cancer Ther (2006) 1.41
Brain viscoelasticity alteration in chronic-progressive multiple sclerosis. PLoS One (2012) 1.41
Platelets contribute to postnatal occlusion of the ductus arteriosus. Nat Med (2009) 1.41
Quantitation of simulated short echo time 1H human brain spectra by LCModel and AMARES. Magn Reson Med (2004) 1.41
Therapeutic implications for the induced levels of Chk1 in Myc-expressing cancer cells. Clin Cancer Res (2011) 1.41
Impact of percutaneous device implantation for closure of patent foramen ovale on valve insufficiencies. Circulation (2009) 1.41
On the abundance of EpCAM on cancer stem cells. Nat Rev Cancer (2009) 1.41
Results of intracoronary stem cell therapy after acute myocardial infarction. Am J Cardiol (2010) 1.40
Targeting T cells to tumor cells using bispecific antibodies. Curr Opin Chem Biol (2013) 1.39
Increased expression of TGF-beta1 and IGF-I in inflammatory stenotic lesions of hemodialysis fistulas. Kidney Int (2002) 1.39
In vivo determination of hepatic stiffness using steady-state free precession magnetic resonance elastography. Invest Radiol (2006) 1.35
Identification of the most common problems by patients with ankylosing spondylitis using the international classification of functioning, disability and health. J Rheumatol (2006) 1.35
Predicting the outcome of ankylosing spondylitis therapy. Ann Rheum Dis (2011) 1.35
Do patients with non-radiographic axial spondylarthritis differ from patients with ankylosing spondylitis? Arthritis Care Res (Hoboken) (2012) 1.34
Rates and predictors of radiographic sacroiliitis progression over 2 years in patients with axial spondyloarthritis. Ann Rheum Dis (2011) 1.33
Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class. J Immunother (2007) 1.30
Descriptions of spinal MRI lesions and definition of a positive MRI of the spine in axial spondyloarthritis: a consensual approach by the ASAS/OMERACT MRI study group. Ann Rheum Dis (2012) 1.30
Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody. Int J Cancer (2002) 1.30
Shear wave group velocity inversion in MR elastography of human skeletal muscle. Magn Reson Med (2006) 1.29
Viscoelasticity-based MR elastography of skeletal muscle. Phys Med Biol (2010) 1.29
Continuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitis. Ann Rheum Dis (2013) 1.29
Mode of cytotoxic action of T cell-engaging BiTE antibody MT110. Immunobiology (2009) 1.28
Eradication of tumors from a human colon cancer cell line and from ovarian cancer metastases in immunodeficient mice by a single-chain Ep-CAM-/CD3-bispecific antibody construct. Cancer Res (2005) 1.28
ASsessment in Ankylosing Spondylitis International Working Group/Spondylitis Association of America recommendations for conducting clinical trials in ankylosing spondylitis. Arthritis Rheum (2005) 1.28
C-peptide colocalizes with macrophages in early arteriosclerotic lesions of diabetic subjects and induces monocyte chemotaxis in vitro. Arterioscler Thromb Vasc Biol (2004) 1.27
In vitro and in vivo activity of MT201, a fully human monoclonal antibody for pancarcinoma treatment. Int J Cancer (2002) 1.26
F-18 NaF PET for detection of bone metastases in lung cancer: accuracy, cost-effectiveness, and impact on patient management. J Bone Miner Res (2003) 1.26